In a study of one pregnant mother with systemic lupus erythematosus and high levels of anti-SSA/Ro antibodies, NYU Langone Health researchers found a drug that blocks the movement of harmful immune proteins (autoantibodies) across the placenta and into the fetal circulation, preventing development of congenital heart block in the newborn.  

A new study by investigators from Mass General Brigham examined 13,547 older women, comparing their step counts over a one week period against their mortality and cardiovascular disease rates over the next decade. They found that achieving just 4,000 steps one or two days per week was associated with lower risk of mortality and cardiovascular disease—and with more steps came even greater benefits, up to a point when risk reductions leveled.

Sudden cardiac death is responsible for an unusually high proportion of deaths in female bodybuilders worldwide, according to research published in the European Heart Journal. The study found the greatest risk among women competing professionally. It also revealed a high proportion of deaths from suicide and homicide among female bodybuilders.

About 9 in 10 U.S. adults have not heard of cardiovascular-kidney-metabolic (CKM) syndrome, a newly defined health condition affecting nearly 90% of adults that includes heart disease, kidney disease, diabetes and obesity, according to a new survey from the American Heart Association.

People's heart health is unlikely to be affected by two types of industrially processed hard fats widely used in everyday food.

Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In “Cardiovascular Research,” his group and a US team showed the therapy improves cardiac function in a mouse model of the disease. 

A landmark international study led by the University of Zurich has shown that artificial intelligence can assess patient risk for the most common type of heart attack more accurately than existing methods. This could enable doctors to guide more personalized treatment decisions for patients.

About The Study: In this study, major adverse cardiovascular event risk varied significantly by medication class, with most protection achieved with sustained treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) followed by sodium-glucose cotransporter-2 inhibitors (SGLT2is), sulfonylureas, and dipeptidyl peptidase-4 inhibitors. The magnitude of benefit of GLP-1RAs over SGLT2is depended on baseline age, atherosclerotic cardiovascular disease, heart failure, and kidney impairment. These results, along with consideration of cost, availability, and collateral clinical benefits, may inform treatment decisions for adults with type 2 diabetes. 

A new scientific statement published today in the American Heart Association's flagship journal Circulation states that significant differences exist in cardiac rehabilitation access, participation and outcomes for women compared to men.